What is subacute sclerosing panencephalitis, including its presentation, diagnosis, and management?

Subacute Sclerosing Panencephalitis (SSPE)

SSPE is a fatal, progressive neurodegenerative disease caused by persistent mutated measles virus in the brain, occurring years after primary measles infection, with highest risk in children infected before age 2 years. 1, 2

Clinical Presentation

SSPE follows a characteristic progressive course that unfolds over months to years:

Stage 1 (Insidious Onset):

• Subtle personality changes and behavioral disturbances
• Progressive cognitive decline and declining intellectual performance
• Psychiatric manifestations are prominent early 3, 4

Stage 2 (Neurological Deterioration):

• Characteristic repetitive myoclonic jerks - the hallmark clinical feature 5
• Seizures and focal neurologic signs
• Movement disorders including dystonia and ataxia
• Visual impairment 3, 1

Stage 3 (Terminal Phase):

• Motor signs progress to akinetic mutism
• Vegetative state
• Death typically within 1-3 years of diagnosis, though prolonged survival has been documented with early treatment 1, 2, 4

Diagnosis

The diagnosis is established by the combination of typical clinical symptoms, strong intrathecal synthesis of measles antibodies, and characteristic EEG findings. 5

Essential Diagnostic Criteria:

CSF Analysis:

• Elevated antimeasles antibodies in CSF (elevated titer is diagnostic) 3, 6
• CSF antibodies and PCR for measles virus 3
• Detection of viral RNA in brain tissue if biopsy performed 3

EEG Findings:

• Bilateral synchronous periodic sharp and slow wave complexes (Radermecker complexes) 7, 3
• Well-defined periodic complexes with 1:1 relationship with myoclonic jerks 3

Neuroimaging (MRI preferred):

• White matter hyperintensities on T2/FLAIR sequences
• Cerebral atrophy
• Demyelination patterns 1, 4

Brain biopsy is indicated only when CSF serology is negative or equivocal, to assess for inclusion bodies, measles virus antigens, or viral RNA 6

Epidemiology and Risk Factors

• Occurs 6-11 per 100,000 measles cases 8
• Highest risk: children infected with measles before age 5 years, particularly under age 2 1, 8
• Latency period averages 6 years between measles infection and SSPE onset 4
• Disproportionately affects low- and middle-income countries with low vaccination coverage 1, 2
• Children with or exposed to HIV infection may be at increased risk 8

Treatment

Treatment remains challenging with no cure; combination therapy with isoprinosine and interferon-α offers the best chance for disease stabilization, though most patients progress to death. 1, 6

Antiviral and Immunomodulatory Therapy:

The IDSA guidelines recommend:

• Intrathecal ribavirin for SSPE (C-III recommendation) 3
• Ribavirin for measles encephalitis (investigational for life-threatening disease; C-III) 3

Recent evidence suggests:

• Intraventricular human lymphoblastoid interferon-α combined with oral inosiplex (isoprinosine) showed highest rates of stabilization or improvement 6
• Newer agents including favipiravir and aprepitant offer emerging hope 1
• Ribavirin, amantadine, and immunoglobulins have been used with variable results 5, 6

Critical caveat: Optimal application regimens have not been established due to absence of common diagnostic and clinical standards 5. Early and combined therapy appears most beneficial for prolonged survival and disease stabilization 1.

Symptomatic Management:

For myoclonic jerks and seizures:

• Carbamazepine (most frequently used) 5, 8
• Levetiracetam 5
• Clobazam 5

Supportive and palliative care:

• Essential for all patients given progressive disability 4, 8
• Avoidance of secondary complications associated with immobility
• Nutritional support and aspiration prevention

Prognosis

SSPE is invariably fatal in 95% of cases, with death occurring within 5 years of diagnosis; only 5% undergo spontaneous remission. 4 However, reports of prolonged survival and disease stabilization exist, particularly with early and combined therapy 1.

Prevention

The only effective protection strategy against SSPE is measles vaccination. 9 SSPE is entirely preventable through maintenance of high measles immunization rates in the population 6, 9. The COVID-19 pandemic's adverse impact on measles vaccination rates has increased SSPE risk globally, highlighting urgent need for robust immunization campaigns 1, 2.

Common Pitfalls:

• Delayed diagnosis due to subtle early psychiatric symptoms being attributed to other causes
• Failure to consider SSPE in all patients with unexplained acquired neurological symptoms 5
• Inadequate vaccination coverage in resource-limited settings perpetuating disease burden 2
• Limited access to diagnostic testing (CSF measles antibodies, EEG) in low- and middle-income countries 2